CellProthera Announced New Board of Directors: Capabilities to Enhance Development and Commercialization Plan
International board features extensive background in cardiology, pharma development, and commercial development
Mulhouse, France, March 27, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized among shareholders and new investors. The new board features both investors and independent members, with a wealth of expertise in global biopharma cardiovascular development and entrepreneurship. The board was assembled to support fundraising for the Phase 3 clinical trial of CellProthera’s lead asset, ProtheraCytes®, and oversee its advancement into commercialization.
“This new team is uniquely positioned as we enter CellProthera’s next phase, ensuring we are sufficiently capitalized and prepared to advance ProtheraCytes into a pivotal Phase 3 study in patients who have suffered a heart attack, with the aim of preventing further cardiac deterioration,” said Koch, who is Chairman of the Board. “We would like to thank the previous board, as we would not be at this pivotal moment today without their dedication and leadership, overseeing the company as it successfully completed Phase 2 testing.”
Providing continuity on the board is Professor Philippe Hénon, M.D., CellProthera co-founder and former Chairman of the Board. Joining Professor Hénon and Mr. Koch, who is also Chairman and CEO of industrial and financial assets management firm Zuber-Laederich, on the board are the following:
- Steven Hildemann, M.D., Ph.D., independent member, board certified in Internal Medicine and Cardiology, adjunct professor of medicine, University of Freiburg, former Global CMO for Merck and EVP and CMO at Ipsen.
- Elsy Boglioli, independent member, Chair of TreeFrog Therapeutics, independent Director in multiple biotech companies, previously Executive VP and COO of Cellectis, and Partner and Managing Director at the Boston Consulting Group.
- Jean-Pascal Tranié, independent member, Founder of Aloe PE Investment fund, co-founder of PepKon, board member at Allogenica and Polygon, and former CEO of Numericable.
- Henri Assaf, CellProthera early investor, co-founder and Managing Director of SAB for 30 years and investor in over 15 startups.
- Francois Anger, CellProthera early investor, former Chairman and co-founder of Addmedica (sold to Merieux), CFO of OTL Pharma, and Director of Economic Affairs at Pfizer.
About CellProthera
CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction. CellProthera has developed a unique GMP-compliant cell expansion process as well as a proprietary automation technology for in vitro production of a large quantity of purified, expanded CD34+ stem cells. Its lead therapy ProtheraCytes®, is an autologous cell therapy targeted to regenerate various damaged tissues, including cardiac tissue. ProtheraCytes is registered as an Advanced Therapy Medicinal Product – ATMP – by the European Medicines Agency (EMA). CellProthera’s proprietary technology platform comprises an automated expansion device called StemXpand® and its single use kit StemPack®. CellProthera is headquartered in Mulhouse, France.
